WO2001085202A3 - Procede d'introduction de molecules dans des cellules - Google Patents

Procede d'introduction de molecules dans des cellules Download PDF

Info

Publication number
WO2001085202A3
WO2001085202A3 PCT/GB2001/001970 GB0101970W WO0185202A3 WO 2001085202 A3 WO2001085202 A3 WO 2001085202A3 GB 0101970 W GB0101970 W GB 0101970W WO 0185202 A3 WO0185202 A3 WO 0185202A3
Authority
WO
WIPO (PCT)
Prior art keywords
skeletal muscle
mammal
antigen
injection site
electrodes
Prior art date
Application number
PCT/GB2001/001970
Other languages
English (en)
Other versions
WO2001085202A2 (fr
Inventor
Iacob Mathiesen
Stig Tollefsen
Original Assignee
Electrofect As
Iacob Mathiesen
Stig Tollefsen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/055,084 external-priority patent/US6110161A/en
Application filed by Electrofect As, Iacob Mathiesen, Stig Tollefsen filed Critical Electrofect As
Priority to AU54932/01A priority Critical patent/AU5493201A/en
Priority to EP01928065A priority patent/EP1280550A2/fr
Publication of WO2001085202A2 publication Critical patent/WO2001085202A2/fr
Publication of WO2001085202A3 publication Critical patent/WO2001085202A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/18—Applying electric currents by contact electrodes
    • A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
    • A61N1/325—Applying electric currents by contact electrodes alternating or intermittent currents for iontophoresis, i.e. transfer of media in ionic state by an electromotoric force into the body
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/18—Applying electric currents by contact electrodes
    • A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
    • A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
    • A61N1/36003—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation of motor muscles, e.g. for walking assistance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/18—Applying electric currents by contact electrodes
    • A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
    • A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/18—Applying electric currents by contact electrodes
    • A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
    • A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
    • A61N1/36014—External stimulators, e.g. with patch electrodes
    • A61N1/36017—External stimulators, e.g. with patch electrodes with leads or electrodes penetrating the skin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Cette invention se rapporte à un procédé servant à déclencher une réponse du système immunitaire chez un mammifère, ce procédé consistant: à injecter un premier antigène dans un premier site d'injection dans un muscle du squelette de ce mammifère; à injecter éventuellement un polynucléotide codant fonctionnellement un second antigène dans un second site d'injection dans un muscle du squelette de ce mammifère; à placer des électrodes dans ce muscle du squelette, pour que le courant passant entre ces électrodes traverse le premier et/ou le second site d'injection; et à stimuler électriquement ce muscle entre les électrodes à l'aide d'un courant électrique ayant une intensité de champ dans le muscle comprise entre 10 et 300 V/cm, de façon à favoriser l'assimilation cellulaire dudit premier antigène et/ou dudit polynucléotide.
PCT/GB2001/001970 1997-04-03 2001-05-04 Procede d'introduction de molecules dans des cellules WO2001085202A2 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU54932/01A AU5493201A (en) 1997-04-03 2001-05-04 Method for introduction of molecules into cells
EP01928065A EP1280550A2 (fr) 1997-04-03 2001-05-04 Procede d'introduction de molecules dans des cellules

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US4259497P 1997-04-03 1997-04-03
US09/055,084 US6110161A (en) 1997-04-03 1998-04-03 Method for introducing pharmaceutical drugs and nucleic acids into skeletal muscle
US09/565,140 2000-05-05
US09/565,140 US6261281B1 (en) 1997-04-03 2000-05-05 Method for genetic immunization and introduction of molecules into skeletal muscle and immune cells
US09/899,561 US20020038112A1 (en) 1997-04-03 2001-07-05 Method for genetic immunization and introduction of molecules into skeletal muscle and immune cells
US10/141,561 US6610044B2 (en) 1997-04-03 2002-05-07 Method for genetic immunization
US10/620,271 US6958060B2 (en) 1997-04-03 2003-07-14 Method for muscle delivery of drugs, nucleic acids and other compounds

Publications (2)

Publication Number Publication Date
WO2001085202A2 WO2001085202A2 (fr) 2001-11-15
WO2001085202A3 true WO2001085202A3 (fr) 2002-03-28

Family

ID=35910568

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2001/001970 WO2001085202A2 (fr) 1997-04-03 2001-05-04 Procede d'introduction de molecules dans des cellules

Country Status (4)

Country Link
US (6) US6261281B1 (fr)
EP (1) EP1280550A2 (fr)
AU (1) AU5493201A (fr)
WO (1) WO2001085202A2 (fr)

Families Citing this family (210)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5993434A (en) * 1993-04-01 1999-11-30 Genetronics, Inc. Method of treatment using electroporation mediated delivery of drugs and genes
US5702359A (en) * 1995-06-06 1997-12-30 Genetronics, Inc. Needle electrodes for mediated delivery of drugs and genes
US6261281B1 (en) * 1997-04-03 2001-07-17 Electrofect As Method for genetic immunization and introduction of molecules into skeletal muscle and immune cells
US20040229363A1 (en) * 1998-06-24 2004-11-18 Ed Nolan High efficiency transfection based on low electric field strength, long pulse length
EP1470161A1 (fr) * 2002-01-18 2004-10-27 Inovio AS Constructions d'adn d'anticorps bispecifique pour administration intramusculaire muscle
CA2476452A1 (fr) * 2002-02-15 2003-08-28 Zycos Inc. Procedes d'electroporation pour introduire des agents bioactifs dans des cellules
US7245963B2 (en) * 2002-03-07 2007-07-17 Advisys, Inc. Electrode assembly for constant-current electroporation and use
US8209006B2 (en) * 2002-03-07 2012-06-26 Vgx Pharmaceuticals, Inc. Constant current electroporation device and methods of use
US8150520B2 (en) 2002-04-08 2012-04-03 Ardian, Inc. Methods for catheter-based renal denervation
US7756583B2 (en) 2002-04-08 2010-07-13 Ardian, Inc. Methods and apparatus for intravascularly-induced neuromodulation
US20080213331A1 (en) 2002-04-08 2008-09-04 Ardian, Inc. Methods and devices for renal nerve blocking
US8347891B2 (en) 2002-04-08 2013-01-08 Medtronic Ardian Luxembourg S.A.R.L. Methods and apparatus for performing a non-continuous circumferential treatment of a body lumen
US7620451B2 (en) 2005-12-29 2009-11-17 Ardian, Inc. Methods and apparatus for pulsed electric field neuromodulation via an intra-to-extravascular approach
US9308043B2 (en) 2002-04-08 2016-04-12 Medtronic Ardian Luxembourg S.A.R.L. Methods for monopolar renal neuromodulation
US7162303B2 (en) 2002-04-08 2007-01-09 Ardian, Inc. Renal nerve stimulation method and apparatus for treatment of patients
US7853333B2 (en) 2002-04-08 2010-12-14 Ardian, Inc. Methods and apparatus for multi-vessel renal neuromodulation
US8150519B2 (en) 2002-04-08 2012-04-03 Ardian, Inc. Methods and apparatus for bilateral renal neuromodulation
US7653438B2 (en) 2002-04-08 2010-01-26 Ardian, Inc. Methods and apparatus for renal neuromodulation
US8145317B2 (en) 2002-04-08 2012-03-27 Ardian, Inc. Methods for renal neuromodulation
US8131371B2 (en) 2002-04-08 2012-03-06 Ardian, Inc. Methods and apparatus for monopolar renal neuromodulation
US8774922B2 (en) 2002-04-08 2014-07-08 Medtronic Ardian Luxembourg S.A.R.L. Catheter apparatuses having expandable balloons for renal neuromodulation and associated systems and methods
US20070129761A1 (en) 2002-04-08 2007-06-07 Ardian, Inc. Methods for treating heart arrhythmia
US9308044B2 (en) 2002-04-08 2016-04-12 Medtronic Ardian Luxembourg S.A.R.L. Methods for therapeutic renal neuromodulation
US8145316B2 (en) 2002-04-08 2012-03-27 Ardian, Inc. Methods and apparatus for renal neuromodulation
US7617005B2 (en) 2002-04-08 2009-11-10 Ardian, Inc. Methods and apparatus for thermally-induced renal neuromodulation
US6978174B2 (en) 2002-04-08 2005-12-20 Ardian, Inc. Methods and devices for renal nerve blocking
US20070135875A1 (en) 2002-04-08 2007-06-14 Ardian, Inc. Methods and apparatus for thermally-induced renal neuromodulation
US9636174B2 (en) 2002-04-08 2017-05-02 Medtronic Ardian Luxembourg S.A.R.L. Methods for therapeutic renal neuromodulation
US20140018880A1 (en) 2002-04-08 2014-01-16 Medtronic Ardian Luxembourg S.A.R.L. Methods for monopolar renal neuromodulation
US8774913B2 (en) 2002-04-08 2014-07-08 Medtronic Ardian Luxembourg S.A.R.L. Methods and apparatus for intravasculary-induced neuromodulation
EP1545432A4 (fr) * 2002-09-26 2007-03-14 Pfizer Prod Inc Utilisation d'excipients afin d'augmenter la prise d'adn par des cellules musculaires de porc
ATE465753T1 (de) 2002-10-21 2010-05-15 Eisai Inc Zusammensetzungen und verfahren zurbehandlung von krankheiten, die durch das humane papillomavirus vermitteltwerden
US20050287118A1 (en) * 2003-11-26 2005-12-29 Epitomics, Inc. Bacterial plasmid with immunological adjuvant function and uses thereof
US20050277127A1 (en) * 2003-11-26 2005-12-15 Epitomics, Inc. High-throughput method of DNA immunogen preparation and immunization
US7541185B2 (en) * 2003-12-23 2009-06-02 Cythera, Inc. Methods for identifying factors for differentiating definitive endoderm
US7510876B2 (en) 2003-12-23 2009-03-31 Cythera, Inc. Definitive endoderm
US7985585B2 (en) * 2004-07-09 2011-07-26 Viacyte, Inc. Preprimitive streak and mesendoderm cells
US20050266554A1 (en) * 2004-04-27 2005-12-01 D Amour Kevin A PDX1 expressing endoderm
US8647873B2 (en) 2004-04-27 2014-02-11 Viacyte, Inc. PDX1 expressing endoderm
WO2007059007A2 (fr) * 2005-11-14 2007-05-24 Cythera, Inc. Marqueurs d'endoderme definitif
CN112813019A (zh) * 2003-12-23 2021-05-18 维亚希特公司 定形内胚层
US7625753B2 (en) 2003-12-23 2009-12-01 Cythera, Inc. Expansion of definitive endoderm cells
EP2377922B1 (fr) 2004-04-27 2020-04-08 Viacyte, Inc. Endoderme exprimant PDX1
FR2872055B1 (fr) 2004-06-24 2008-02-08 Yves Leon Scherman Dispositif pour le transfert de molecules aux cellules utilisant une force d'origine physique et combinaison permettant la mise en oeuvre du procede
CA2966883A1 (fr) 2004-07-09 2006-02-16 Cythera, Inc. Methodes d'identification de facteurs pour differencier l'endoderme definitif
JP5102030B2 (ja) * 2004-08-13 2012-12-19 ユニバーシティ・オブ・ジョージア・リサーチ・ファウンデイション・インコーポレイテッド ヒト胚性幹細胞における自己再生および分化のための組成物および方法
US7937143B2 (en) 2004-11-02 2011-05-03 Ardian, Inc. Methods and apparatus for inducing controlled renal neuromodulation
US20070048289A1 (en) * 2005-08-31 2007-03-01 Grandjean Pierre A Cellular intervention to treat damaged myocardium
DK1957636T3 (en) 2005-10-27 2018-10-01 Viacyte Inc PDX1-EXPRESSING DORSAL AND VENTRAL FORTARM ENDODERM
US20070253969A1 (en) * 2005-11-14 2007-11-01 Freda Stevenson Materials and methods relating to DNA vaccination
US11254916B2 (en) 2006-03-02 2022-02-22 Viacyte, Inc. Methods of making and using PDX1-positive pancreatic endoderm cells
EP1999253B1 (fr) 2006-03-02 2019-05-22 Viacyte, Inc. Cellules précurseurs endocrines, cellules exprimant des hormones pancréatiques et procédés de productions associés
US7695965B2 (en) 2006-03-02 2010-04-13 Cythera, Inc. Methods of producing pancreatic hormones
US8260411B1 (en) 2006-09-06 2012-09-04 Twin Star Medical, Inc. Conductive injection and aspiration device and method
WO2008048647A1 (fr) * 2006-10-17 2008-04-24 Cythera, Inc. Modulation de la voie de la phosphatidylinositol-3-kinase dans la différentiation des cellules souches embryonnaires humaines
US8524679B2 (en) * 2006-11-08 2013-09-03 Veritas Bio, Llc In vivo delivery of double stranded RNA to a target cell
WO2008063555A2 (fr) 2006-11-17 2008-05-29 Genetronics, Inc. Méthodes accroissant la réponse immunitaire par vaccination assistée par électroporation, et renfort
US7695963B2 (en) 2007-09-24 2010-04-13 Cythera, Inc. Methods for increasing definitive endoderm production
WO2009058564A2 (fr) 2007-11-01 2009-05-07 Maxygen, Inc. Polypeptide immunosuppresseur et acides nucléiques
CN102016023A (zh) * 2008-04-04 2011-04-13 宾夕法尼亚州立大学托管会 使用il-28和组合物的疫苗和免疫治疗及其使用方法
CN101990580A (zh) * 2008-04-04 2011-03-23 宾夕法尼亚州立大学托管会 屈曲病毒蛋白共有序列、编码该屈曲病毒蛋白共有序列的核酸分子和组合物及其使用方法
EP2356227B1 (fr) 2008-11-14 2018-03-28 Viacyte, Inc. Encapsulation de cellules pancréatiques dérivées de cellules souches pluripotentes humaines
US8652129B2 (en) 2008-12-31 2014-02-18 Medtronic Ardian Luxembourg S.A.R.L. Apparatus, systems, and methods for achieving intravascular, thermally-induced renal neuromodulation
US8445663B2 (en) 2009-02-02 2013-05-21 Chrontech Pharma Ab Compositions and methods that enhance an immune response
US20100298697A1 (en) * 2009-05-19 2010-11-25 Medtronic, Inc. Method and devices for improved efficiency of rna delivery to cells
US8207138B2 (en) 2009-05-19 2012-06-26 Medtronic, Inc. Methods and devices for improved efficiency of RNA delivery to cells
EP2477659A4 (fr) 2009-09-14 2014-01-15 Univ Pennsylvania Vaccins et agents immunothérapeutiques comprenant le récepteur alpha il-15 et/ou des molécules d'acide nucléique codant pour celui-ci, et méthodes d'utilisation de ceux-ci
AU2010313132B2 (en) 2009-11-02 2015-01-15 Inovio Pharmaceuticals, Inc. Foot and mouth disease virus (FMDV) consensus proteins, coding sequences therefor and vaccines made therefrom
WO2011073796A2 (fr) 2009-12-16 2011-06-23 Chrontech Pharma Ab Aiguille et dispositif d'injection
US8298820B2 (en) 2010-01-26 2012-10-30 The Trustees Of The University Of Pennsylvania Influenza nucleic acid molecules and vaccines made therefrom
US9034313B2 (en) 2010-02-08 2015-05-19 The Trustees Of The University Of Pennsylvania Nucleic acid molecules encoding rantes, and compositions comprising and methods of using the same
EP3578205A1 (fr) 2010-08-06 2019-12-11 ModernaTX, Inc. Compositions pharmaceutiques a base d'acides nucléiques modifiés et leur utilisation medicale
BR112013007051A2 (pt) 2010-09-27 2019-07-02 Inovio Pharmaceuticals Inc [Us/Is] construções de antígenio de consenso e vacinas feitas dos mesmos e métodos de uso das mesmas para tratar a malária
WO2012045082A2 (fr) 2010-10-01 2012-04-05 Jason Schrum Synthèse d'acides nucléiques et méthodes d'utilisation associées
JP6046041B2 (ja) 2010-10-25 2016-12-14 メドトロニック アーディアン ルクセンブルク ソシエテ ア レスポンサビリテ リミテ 神経変調療法の評価及びフィードバックのためのデバイス、システム、及び方法
US8927692B2 (en) 2010-11-12 2015-01-06 The Trustees Of The University Of Pennsylvania Consensus prostate antigens, nucleic acid molecule encoding the same and vaccine and uses comprising the same
KR20140007404A (ko) 2011-01-31 2014-01-17 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 신규 허피스 항원을 암호화하는 핵산 분자, 이것을 포함하는 백신 및 이것의 사용 방법
US9238679B2 (en) 2011-02-11 2016-01-19 The Trustees Of The University Of Pennslyvania Nucleic acid molecule encoding hepatitis B virus core protein and surface antigen protein and vaccine comprising the same
EA202092990A3 (ru) 2011-02-11 2021-07-30 Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания Молекула нуклеиновой кислоты, кодирующая коровый белок вируса гепатита в, и вакцина, содержащая указанную молекулу
AU2012236099A1 (en) 2011-03-31 2013-10-03 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
WO2012172424A1 (fr) 2011-06-15 2012-12-20 Crontech Pharma Ab Aiguille et dispositif d'injection
EP3662935A1 (fr) 2011-07-11 2020-06-10 Inovio Pharmaceuticals, Inc. Vaccins d'arenavirus de protection croisée et leur procédé d'utilisation
EP2741785B1 (fr) 2011-07-12 2018-09-05 Philadelphia Health and Education Corporation Nouveau vaccin à adn dirigé contre clostridium difficile
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
SG11201400527XA (en) 2011-09-16 2014-04-28 Univ Pennsylvania Rna engineered t cells for the treatment of cancer
WO2013044225A1 (fr) 2011-09-22 2013-03-28 The Trustees Of The University Of Pennsylvania Récepteur immunitaire universel exprimé par des lymphocytes t pour le ciblage d'antigènes divers et multiples
EP3682905B1 (fr) 2011-10-03 2021-12-01 ModernaTX, Inc. Nucléosides, nucléotides et acides nucléiques modifiés et leurs utilisations
WO2013063419A2 (fr) 2011-10-28 2013-05-02 The Trustees Of The University Of Pennsylvania Récepteur immunitaire chimérique spécifique complètement humain, anti-mésothéline pour un ciblage redirigé de cellules exprimant la mésothéline
EA026926B1 (ru) 2011-12-12 2017-05-31 Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания Композиции, содержащие улучшенные генетические конструкции il-12, вакцины, иммунотерапевтические составы и способы их применения
JP6407028B2 (ja) 2011-12-12 2018-10-17 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア ＭＲＳＡのＰＢＰ２ａ及びその断片を含むタンパク質、それをコードする核酸、並びにＭＲＳＡ感染を予防する及び治療するための組成物及びそれらの使用
DK2791160T3 (da) 2011-12-16 2022-05-30 Modernatx Inc Modificerede mrna-sammensætninger
SG11201404284SA (en) 2012-02-22 2014-10-30 Univ Pennsylvania Use of the cd2 signaling domain in second-generation chimeric antigen receptors
WO2013126733A1 (fr) 2012-02-22 2013-08-29 The Trustees Of University Of Pennsylvania Utilisation de récepteurs d'antigène chimériques (car) comportant un costimulateur inductible (icos) afin d'améliorer l'activité antitumorale et la persistance des car
CA2865242A1 (fr) 2012-03-08 2013-09-12 Medtronic Ardian Luxembourg S.A.R.L. Echantillonnage de biomarqueurs dans le contexte de dispositifs de neuromodulation et systemes et procedes associes
AU2013230781B2 (en) 2012-03-08 2015-12-03 Medtronic Af Luxembourg S.A.R.L. Ovarian neuromodulation and associated systems and methods
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
DE18200782T1 (de) 2012-04-02 2021-10-21 Modernatx, Inc. Modifizierte polynukleotide zur herstellung von proteinen im zusammenhang mit erkrankungen beim menschen
US9878056B2 (en) 2012-04-02 2018-01-30 Modernatx, Inc. Modified polynucleotides for the production of cosmetic proteins and peptides
US10040828B2 (en) 2012-04-10 2018-08-07 The Trustees Of The University Of Pennsylvania Human respiratory syncytial virus consensus antigens, nucleic acid constructs and vaccines made therefrom, and methods of using same
KR102351881B1 (ko) 2012-04-12 2022-01-18 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 필로바이러스 공통 항원, 이로부터 제조된 핵산 구조체 및 백신, 및 이를 사용하는 방법
EP3730512A1 (fr) 2012-07-13 2020-10-28 The Trustees of the University of Pennsylvania Renforcement de l'activité des lymphocytes t car grâce à la co-introduction d'un anticorps bispécifique
EP2904106A4 (fr) 2012-10-01 2016-05-11 Univ Pennsylvania Compositions et procédés de ciblage de cellules stromales pour le traitement du cancer
WO2014055657A1 (fr) 2012-10-05 2014-04-10 The Trustees Of The University Of Pennsylvania Utilisation d'une approche trans-signalisation dans des récepteurs d'antigènes chimériques
WO2014064534A2 (fr) 2012-10-05 2014-05-01 Chrontech Pharma Ab Aiguille d'injection, dispositif, compositions immunogènes et procédé d'utilisation
US9598489B2 (en) 2012-10-05 2017-03-21 The Trustees Of The Univeristy Of Pennsylvania Human alpha-folate receptor chimeric antigen receptor
US20140110296A1 (en) 2012-10-19 2014-04-24 Medtronic Ardian Luxembourg S.A.R.L. Packaging for Catheter Treatment Devices and Associated Devices, Systems, and Methods
HRP20220607T1 (hr) 2012-11-26 2022-06-24 Modernatx, Inc. Terminalno modificirana rna
CN104812401B (zh) 2012-12-13 2017-10-13 宾夕法尼亚大学理事会 Wt1疫苗
ES2817903T3 (es) 2013-03-15 2021-04-08 Univ Pennsylvania Proteínas de consenso del virus de la Fiebre Aftosa (VFA), secuencias codificantes y vacunas preparadas a partir de las mismas
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
AU2014228405B2 (en) 2013-03-15 2017-05-11 The Trustees Of The University Of Pennsylvania Cancer vaccines and methods of treatment using the same
WO2014186409A1 (fr) 2013-05-15 2014-11-20 Chrontech Pharma Ab Compositions immunogènes permettant d'inhiber le virus de l'hépatite d
AU2014296038B2 (en) 2013-07-31 2020-09-10 Bioventures, Llc. Compositions for and methods of treating and preventing cancer targeting tumor associated carbohydrate antigens
WO2015048744A2 (fr) 2013-09-30 2015-04-02 Moderna Therapeutics, Inc. Polynucléotides codant des polypeptides de modulation immunitaire
EP3052521A1 (fr) 2013-10-03 2016-08-10 Moderna Therapeutics, Inc. Polynucléotides codant pour un récepteur de lipoprotéines de faible densité
EP3080159A4 (fr) 2013-12-13 2017-08-02 The Trustees Of The University Of Pennsylvania Constructions d'anticorps d'adn et procédé d'utilisation
US11028143B2 (en) 2014-01-21 2021-06-08 Novartis Ag Enhanced antigen presenting ability of RNA CAR T cells by co-introduction of costimulatory molecules
US9980766B1 (en) 2014-03-28 2018-05-29 Medtronic Ardian Luxembourg S.A.R.L. Methods and systems for renal neuromodulation
US10194980B1 (en) 2014-03-28 2019-02-05 Medtronic Ardian Luxembourg S.A.R.L. Methods for catheter-based renal neuromodulation
US10194979B1 (en) 2014-03-28 2019-02-05 Medtronic Ardian Luxembourg S.A.R.L. Methods for catheter-based renal neuromodulation
US11471487B2 (en) 2014-10-31 2022-10-18 The Trustees Of The University Of Pennsylvania Compositions and methods of stimulating and expanding T cells
EP3215168B1 (fr) 2014-10-31 2023-08-02 The Trustees of the University of Pennsylvania Modification de l'expression génétique dans des lymphocytes t modifiés et utilisations associées
CA2969214A1 (fr) 2014-12-01 2016-06-09 The Trustees Of The University Of Pennsylvania Constructions d'anticorps d'adn et leur procede d'utilisation
AU2015380397B2 (en) 2015-01-31 2021-10-21 The Trustees Of The University Of Pennsylvania Compositions and methods for T cell delivery of therapeutic molecules
RU2754661C2 (ru) 2015-05-01 2021-09-06 Дзе Реджентс Оф Дзе Юниверсити Оф Калифорния Гликанзависимые иммунотерапевтические молекулы
US11007260B2 (en) 2015-07-21 2021-05-18 Modernatx, Inc. Infectious disease vaccines
US11364292B2 (en) 2015-07-21 2022-06-21 Modernatx, Inc. CHIKV RNA vaccines
CN108348551A (zh) 2015-08-28 2018-07-31 宾夕法尼亚大学董事会 表达嵌合细胞内信号传导分子的细胞的方法和组合物
WO2017055522A1 (fr) 2015-09-29 2017-04-06 Academisch Medisch Centrum Protéines env stabilisées du vih
WO2017070616A2 (fr) 2015-10-22 2017-04-27 Modernatx, Inc. Vaccins contre les maladies sexuellement transmissibles
WO2017070624A1 (fr) 2015-10-22 2017-04-27 Modernatx, Inc. Vaccins contre des maladies tropicales
PE20181529A1 (es) 2015-10-22 2018-09-26 Modernatx Inc Vacunas de acido nucleico para el virus varicela-zoster (vzv)
JP7123800B2 (ja) 2016-02-05 2022-08-23 イノビオ ファーマシューティカルズ，インコーポレイティド がんのワクチン及びそれを用いた処置の方法
EP3432924A1 (fr) 2016-03-23 2019-01-30 Novartis AG Mini-corps sécrétés par des cellules et leurs usages
EP3443107A1 (fr) 2016-04-13 2019-02-20 Synthetic Genomics, Inc. Systèmes de réplicon d'artérivirus recombinant et utilisations correspondantes
US10233419B2 (en) 2016-06-30 2019-03-19 Zymergen Inc. Apparatuses and methods for electroporation
JP2018035137A (ja) 2016-07-13 2018-03-08 マブイミューン ダイアグノスティックス エイジーＭａｂｉｍｍｕｎｅ Ｄｉａｇｎｏｓｔｉｃｓ Ａｇ 新規な抗線維芽細胞活性化タンパク質（ｆａｐ）結合薬剤およびその使用
EP3526332B1 (fr) 2016-10-17 2024-06-26 Janssen Pharmaceuticals, Inc. Système réplicon recombinant de virus et leurs utilisations
EP3538146A4 (fr) 2016-11-11 2020-07-15 ModernaTX, Inc. Vaccin antigrippal
JP2020500536A (ja) 2016-12-05 2020-01-16 シンセティック ジェノミクス インコーポレーテッド 遺伝子発現増強のための組成物および方法
EP3551193A4 (fr) 2016-12-08 2020-08-19 Modernatx, Inc. Vaccins à acide nucléique contre des virus respiratoires
EP3595713A4 (fr) 2017-03-15 2021-01-13 ModernaTX, Inc. Vaccin contre le virus respiratoire syncytial
US11752206B2 (en) 2017-03-15 2023-09-12 Modernatx, Inc. Herpes simplex virus vaccine
US11576961B2 (en) 2017-03-15 2023-02-14 Modernatx, Inc. Broad spectrum influenza virus vaccine
US11045540B2 (en) 2017-03-15 2021-06-29 Modernatx, Inc. Varicella zoster virus (VZV) vaccine
EP3672983A1 (fr) 2017-08-26 2020-07-01 Academisch Medisch Centrum Immunogènes glycoprotéiques d'enveloppe de vih améliorés
US10653767B2 (en) 2017-09-14 2020-05-19 Modernatx, Inc. Zika virus MRNA vaccines
EP3723812A4 (fr) 2017-12-13 2022-02-16 Inovio Pharmaceuticals, Inc. Vaccins anticancer ciblant muc16 et leurs utilisations
JP7352547B2 (ja) 2017-12-13 2023-09-28 イノビオ ファーマシューティカルズ，インコーポレイティド メソセリンを標的とするがんワクチンおよびその使用
ES2938900T3 (es) 2017-12-13 2023-04-17 Inovio Pharmaceuticals Inc Vacunas contra el cáncer dirigidas al PRAME y usos de las mismas
US11389531B2 (en) 2017-12-19 2022-07-19 Janssen Sciences Ireland Unlimited Company Methods and apparatus for the delivery of hepatitis B virus (HBV) vaccines
WO2019123252A1 (fr) 2017-12-19 2019-06-27 Janssen Sciences Ireland Unlimited Company Vaccins contre le virus de l'hépatite b (vhb) et utilisations associées
MX2020006471A (es) 2017-12-19 2020-09-22 Janssen Sciences Ireland Unlimited Co Metodos y composiciones para inducir una respuesta inmune contra el virus de hepatitis b (hbv).
EA202091516A1 (ru) 2017-12-19 2020-11-03 Янссен Сайенсиз Айрлэнд Анлимитед Компани Способы и композиции для индукции иммунного ответа против вируса гепатита b (hbv)
EA202091513A1 (ru) 2017-12-19 2020-09-09 Янссен Сайенсиз Айрлэнд Анлимитед Компани Вакцины против вируса гепатита b (hbv) и их применение
CA3086267A1 (fr) 2017-12-29 2019-07-04 Cellectis Procede d'amelioration de la production de lymphocytes t car
KR20200111729A (ko) 2018-01-19 2020-09-29 얀센 파마슈티칼즈, 인코포레이티드 재조합 레플리콘 시스템을 이용한 면역 반응 유도 및 증진
MA54676A (fr) 2018-01-29 2021-11-17 Modernatx Inc Vaccins à base d'arn contre le vrs
WO2020092455A2 (fr) 2018-10-29 2020-05-07 The Broad Institute, Inc. Atlas de transcription de lymphocytes car-t
US11351242B1 (en) 2019-02-12 2022-06-07 Modernatx, Inc. HMPV/hPIV3 mRNA vaccine composition
WO2020190750A1 (fr) 2019-03-15 2020-09-24 Modernatx, Inc. Vaccins à base d'arn contre le vih
WO2020191102A1 (fr) 2019-03-18 2020-09-24 The Broad Institute, Inc. Systèmes et protéines crispr de type vii
US11090336B2 (en) 2019-03-27 2021-08-17 The Trustees Of The University Of Pennsylvania Tn-MUC1 chimeric antigen receptor (CAR) T cell therapy
CA3140708A1 (fr) 2019-06-18 2020-12-24 Helen Horton Association de vaccins contre le virus de l'hepatite b (vhb) et de derives de pyridopyrimidine
MA56533A (fr) 2019-06-18 2022-04-27 Janssen Sciences Ireland Unlimited Co Combinaison de vaccins contre le virus de l'hépatite b (vhb) et d'anticorps anti-pd-1
US20220305117A1 (en) 2019-06-18 2022-09-29 Janssen Sciences Ireland Unlimited Company Combination of hepatitis b virus (hbv) vaccines and hbv-targeting rnai
US20220324916A1 (en) 2019-06-18 2022-10-13 Janssen Sciences Ireland Unlimited Company Hepatitis B Virus (HBV) Vaccines and Uses Thereof
WO2020255022A1 (fr) 2019-06-18 2020-12-24 Janssen Sciences Ireland Unlimited Company Combinaison de vaccins contre le virus de l'hépatite b (vhb) et de dérivés d'aminopyridine en tant qu'inhibiteurs de hpk1
WO2020254876A1 (fr) 2019-06-18 2020-12-24 Janssen Sciences Ireland Unlimited Company Administration de particules de type viral de vaccins contre le virus de l'hépatite b (vhb)
WO2020255014A1 (fr) 2019-06-18 2020-12-24 Janssen Sciences Ireland Unlimited Company Construction de l'interleukine 12 recombinante et ses utilisations
WO2020255016A1 (fr) 2019-06-18 2020-12-24 Janssen Sciences Ireland Unlimited Company Combinaison de vaccins contre le virus de l'hépatite b (vhb) et de dérivés de dihydropyrimidine en tant que modulateurs de l'assemblage des capsides
US20220305116A1 (en) 2019-06-18 2022-09-29 Janssen Sciences lreland Unlimited Company Combination of hepatitis b virus (hbv) vaccines and capsid assembly modulators being sulfonamide derivatives
US20220233526A1 (en) 2019-06-18 2022-07-28 Janssen Sciences Ireland Unlimited Company Combination of hepatitis b virus (hbv) vaccines and dihydropyrimidine derivatives as capsid assembly modulators
CA3140690A1 (fr) 2019-06-18 2020-12-24 Helen Horton Combinaison de vaccins contre le virus de l'hepatite b (vhb) et de derives de dihydropyrimidine en tant que modulateurs d'assemblage de capside
WO2020255042A1 (fr) 2019-06-18 2020-12-24 Janssen Sciences Ireland Unlimited Company Combinaison de vaccins contre le virus de l'hépatite b (vhb) et d'un dérivé de pyrimidine
CA3140588A1 (fr) 2019-06-18 2020-12-24 Helen Horton Combinaison de vaccins contre le virus de l'hepatite b (vhb) et d'inhibiteur de pdl1 ou pd1 a petite molecule
WO2020255019A1 (fr) 2019-06-18 2020-12-24 Janssen Sciences Ireland Unlimited Company Combinaison de vaccins contre le virus de l'hépatite b (vhb) et d'un dérivé de la quinazoline
WO2020255020A1 (fr) 2019-06-18 2020-12-24 Janssen Sciences Ireland Unlimited Company Association de vaccins contre le virus de l'hépatite b (vhb) et d'inhibiteurs de pd-l1
AU2020297008A1 (en) 2019-06-18 2022-02-17 Janssen Sciences Ireland Unlimited Company Combination of hepatitis B virus (HBV) vaccines and HBV-targeting RNAi
CA3140707A1 (fr) 2019-06-18 2020-12-24 Helen Horton Association de vaccins contre le virus de l'hepatite b (vhb) et de derives de quinazoline
WO2020255035A1 (fr) 2019-06-18 2020-12-24 Janssen Sciences Ireland Unlimited Company Combinaison de vaccins contre le virus de l'hépatite b (vhb) et de dérivés de pyrimidine
WO2020255010A1 (fr) 2019-06-18 2020-12-24 Janssen Sciences Ireland Unlimited Company Combinaison d'une construction d'interleukine 12 recombinante et de vaccins contre le virus de l'hépatite b (vhb)
WO2020255013A1 (fr) 2019-06-18 2020-12-24 Janssen Sciences Ireland Unlimited Company Combinaison de vaccins contre le virus de l'hépatite b (vhb) et de modulateurs d'assemblage de capside qui sont des dérivés d'amide
CA3143680A1 (fr) 2019-06-18 2020-12-24 Janssen Sciences Ireland Unlimited Company Combinaison de vaccins contre le virus de l'hepatite b (vhb) et d'anticorps anti-pd-1 ou anti-pd-l1
WO2020255062A1 (fr) 2019-06-20 2020-12-24 Janssen Sciences Ireland Unlimited Company Administration de nanoparticules lipidiques ou de liposomes de vaccins contre le virus de l'hépatite b (vhb)
MA56534A (fr) 2019-06-20 2022-04-27 Janssen Sciences Ireland Unlimited Co Administration par nanoporteurs glucidiques, de vaccins contre le virus de l'hépatite b (vhb)
US20230000543A1 (en) * 2019-11-27 2023-01-05 North Carolina State University Methods for controlling treatment volumes, thermal gradients, muscle stimulation, and immune responses in pulsed electric field treatments
CA3174103A1 (fr) 2020-03-06 2021-09-10 Go Therapeutics, Inc. Anticorps anti-glyco-cd44 et leurs utilisations
WO2021191871A1 (fr) 2020-03-27 2021-09-30 Dcprime B.V. Utilisation in vivo de cellules modifiées d'origine leucémique pour améliorer l'efficacité d'une thérapie cellulaire adoptive
EP4126028A1 (fr) 2020-03-27 2023-02-08 Svenska Vaccinfabriken Produktion AB Compositions et méthodes de traitement et de prévention des coronavirus
CA3172449A1 (fr) 2020-03-27 2021-09-30 Erik Hans MANTING Utilisation ex vivo de cellules modifiees d'origine leucemique pour ameliorer l'efficacite d'une therapie cellulaire adoptive
US20230272378A1 (en) 2020-06-12 2023-08-31 University Of Rochester ENCODING AND EXPRESSION OF ACE-tRNAs
BR112022027038A2 (pt) 2020-07-08 2023-01-24 Janssen Sciences Ireland Unlimited Co Vacinas de replicon de rna contra hbv
US20230372484A1 (en) 2020-09-14 2023-11-23 Vor Biopharma Inc. Chimeric antigen receptors for treatment of cancer
CA3196677A1 (fr) 2020-11-05 2022-05-12 Erik Hans MANTING Utilisation d'antigenes independants de tumeurs dans des immunotherapies
WO2022133230A1 (fr) 2020-12-18 2022-06-23 Janssen Pharmaceuticals, Inc. Polythérapie pour le traitement d'une infection par le virus de l'hépatite b
WO2022146654A1 (fr) 2020-12-28 2022-07-07 Janssen Pharmaceuticals, Inc. Nucléases effectrices de type activateur de transcription (talens) ciblant le vhb
WO2022187591A1 (fr) 2021-03-05 2022-09-09 Go Therapeutics, Inc. Anticorps anti-glyco-cd44 et leurs utilisations
KR20230157388A (ko) 2021-03-12 2023-11-16 멘두스 비.브이. 백신접종의 방법 및 cd47 차단의 용도
WO2023010118A1 (fr) 2021-07-29 2023-02-02 Vor Biopharma Inc. Systèmes rapporteurs sensibles à nfat pour évaluer l'activation d'un récepteur antigénique chimérique et méthodes de fabrication et d'utilisation de ceux-ci
EP4376877A2 (fr) 2021-07-29 2024-06-05 Vor Biopharma Inc. Récepteurs antigéniques chimériques pour le traitement du cancer
AU2022324456A1 (en) 2021-08-05 2024-02-15 Go Therapeutics, Inc. Anti-glyco-muc4 antibodies and their uses
KR20240101546A (ko) 2021-09-03 2024-07-02 고 테라퓨틱스, 인크. 항-글리코-lamp1 항체 및 그의 용도
CN118354789A (zh) 2021-09-03 2024-07-16 Go医疗股份有限公司 抗糖-cMET抗体及其用途
US20230295244A1 (en) 2021-09-29 2023-09-21 Svenska Vaccinfabriken Produktion Ab Compositions and methods for treating and preventing coronaviruses
WO2023150753A1 (fr) 2022-02-07 2023-08-10 University Of Rochester Séquences optimisées pour une expression d'adn améliorée et/ou une suppression de mutation non sens
US20240002800A1 (en) 2022-05-16 2024-01-04 Mendus B.V. Use of leukemia-derived cells for enhancing natural killer (nk) cell therapy
WO2023233290A1 (fr) 2022-05-31 2023-12-07 Janssen Sciences Ireland Unlimited Company Agents d'arni ciblant pd-l1
WO2024129459A1 (fr) 2022-12-16 2024-06-20 University Of Rochester Réparation d'un dysfonctionnement de la barrière dans l'œsophage

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998043702A2 (fr) * 1997-04-03 1998-10-08 Iacob Mathiesen Methode pour introduire des medicaments et des acides nucleiques dans le muscle squelettique
WO1999001175A1 (fr) * 1997-06-30 1999-01-14 Rhone-Poulenc Rorer S.A. Dispositif permettant un transfert in vivo optimise de vecteurs d'acides nucleiques dans des tissus
WO2000045823A1 (fr) * 1999-02-08 2000-08-10 Chiron Corporation Augmentation electriquement induite de l'immunite et de l'efficacite de vaccins d'adn in vivo

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0239267B2 (ja) 1984-06-12 1990-09-04 Intaa Noba Kk Inionchunyushikichiryosochi
US4702732A (en) * 1984-12-24 1987-10-27 Trustees Of Boston University Electrodes, electrode assemblies, methods, and systems for tissue stimulation and transdermal delivery of pharmacologically active ligands
US4596556A (en) * 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
NZ219392A (en) 1986-02-28 1989-05-29 Smithkline Beckman Corp Production of an immortalised primary cell line
US5389069A (en) 1988-01-21 1995-02-14 Massachusetts Institute Of Technology Method and apparatus for in vivo electroporation of remote cells and tissue
EP0398960B1 (fr) 1988-01-21 1995-12-06 Massachusetts Institute Of Technology Transport de molecules a travers les tissus par electroporation
US4913699A (en) * 1988-03-14 1990-04-03 Parsons James S Disposable needleless injection system
US5501662A (en) 1992-05-22 1996-03-26 Genetronics, Inc. Implantable electroporation method and apparatus for drug and gene delivery
US5304120A (en) 1992-07-01 1994-04-19 Btx Inc. Electroporation method and apparatus for insertion of drugs and genes into endothelial cells
US5507724A (en) 1992-07-01 1996-04-16 Genetronics, Inc. Electroporation and iontophoresis apparatus and method for insertion of drugs and genes into cells
US5273525A (en) 1992-08-13 1993-12-28 Btx Inc. Injection and electroporation apparatus for drug and gene delivery
US5318514A (en) 1992-08-17 1994-06-07 Btx, Inc. Applicator for the electroporation of drugs and genes into surface cells
US5468223A (en) 1992-11-30 1995-11-21 C.N.R.S. Paris Electrochemotherapy
JP3360865B2 (ja) * 1993-03-26 2003-01-07 東海旅客鉄道株式会社 列車速度制御方法及び装置
FR2703253B1 (fr) 1993-03-30 1995-06-23 Centre Nat Rech Scient Applicateur d'impulsions electriques pour traitement de tissus biologiques.
US5993434A (en) 1993-04-01 1999-11-30 Genetronics, Inc. Method of treatment using electroporation mediated delivery of drugs and genes
US5439440A (en) 1993-04-01 1995-08-08 Genetronics, Inc. Electroporation system with voltage control feedback for clinical applications
US5702359A (en) 1995-06-06 1997-12-30 Genetronics, Inc. Needle electrodes for mediated delivery of drugs and genes
IL108775A (en) 1994-02-25 2003-09-17 Univ Ramot Method for efficient incorporation of molecules into cells
US5736524A (en) * 1994-11-14 1998-04-07 Merck & Co.,. Inc. Polynucleotide tuberculosis vaccine
US5810762A (en) 1995-04-10 1998-09-22 Genetronics, Inc. Electroporation system with voltage control feedback for clinical applications
JPH10502858A (ja) 1995-05-02 1998-03-17 フィリップス エレクトロニクス エヌ ベー 対象の磁気共鳴画像化方法及び装置
US5730723A (en) * 1995-10-10 1998-03-24 Visionary Medical Products Corporation, Inc. Gas pressured needle-less injection device and method
US6041252A (en) 1995-06-07 2000-03-21 Ichor Medical Systems Inc. Drug delivery system and method
AU6855796A (en) 1995-08-29 1997-03-19 Cbr Laboratories, Inc. In vivo electroporation of cells
US5944710A (en) 1996-06-24 1999-08-31 Genetronics, Inc. Electroporation-mediated intravascular delivery
PT948319E (pt) 1996-12-23 2004-02-27 Ct Nat De La Rech Scientif Cnr Celulas encapsuladas produtoras de anticorpos
FR2758569B1 (fr) 1997-01-20 1999-04-02 Centre Nat Rech Scient Materiel biologique pour le traitement d'un mammifere par transfert de gene d'anticorps et composition pharmaceutique le concernant
US20020168339A1 (en) * 1997-01-20 2002-11-14 Marc Piechaczyk Biological material for treating a mammal by antibody gene transfer and pharmaceutical composition containing same
US6261281B1 (en) * 1997-04-03 2001-07-17 Electrofect As Method for genetic immunization and introduction of molecules into skeletal muscle and immune cells
EP0991425B1 (fr) 1997-06-30 2005-03-09 Institut Gustave Roussy Amelioration du transfert d'acide nucleique dans les cellules d'organismes eucaryotes pluricellulaires et combinaison permettant la mise en oeuvre du procede
US5965925A (en) 1997-10-22 1999-10-12 Artisan Components, Inc. Integrated circuit layout methods and layout structures
US6009347A (en) 1998-01-27 1999-12-28 Genetronics, Inc. Electroporation apparatus with connective electrode template
US6440944B2 (en) * 1998-10-16 2002-08-27 Genvec, Inc. Methods of administering adenoviral vectors
US20030018006A1 (en) 2001-06-29 2003-01-23 Academia Sinica In vivo electroporation-mediated cytokine/immunocytokine-based antitumoral gene

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998043702A2 (fr) * 1997-04-03 1998-10-08 Iacob Mathiesen Methode pour introduire des medicaments et des acides nucleiques dans le muscle squelettique
WO1999001175A1 (fr) * 1997-06-30 1999-01-14 Rhone-Poulenc Rorer S.A. Dispositif permettant un transfert in vivo optimise de vecteurs d'acides nucleiques dans des tissus
WO2000045823A1 (fr) * 1999-02-08 2000-08-10 Chiron Corporation Augmentation electriquement induite de l'immunite et de l'efficacite de vaccins d'adn in vivo

Non-Patent Citations (17)

* Cited by examiner, † Cited by third party
Title
BACHY MONIQUE ET AL: "Electric pulses increase the immunogenicity of an influenza DNA vaccine injected intramuscularly in the mouse.", VACCINE, vol. 19, no. 13-14, 8 February 2001 (2001-02-08), pages 1688 - 1693, XP002183367, ISSN: 0264-410X *
BIOELECTROCHEMISTRY AND BIOENERGETICS, vol. 49, no. 1, October 1999 (1999-10-01), pages 11 - 20, ISSN: 0302-4598 *
CURR OPIN MOL THER, (2000 APR) 2 (2) 150-4. REF: 39 *
DANKO I ET AL: "PHARMACOLOGICAL ENHANCEMENT OF IN VIVO FOREIGN GENE EXPRESSION IN MUSCLE", GENE THERAPY, MACMILLAN PRESS LTD., BASINGSTOKE, GB, vol. 1, no. 2, March 1994 (1994-03-01), pages 114 - 121, XP001030901, ISSN: 0969-7128 *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 20 January 1998 (1998-01-20), LE BORGNE SYLVIE ET AL: "In vivo induction of specific cytotoxic T lymphocytes in mice and rhesus macaques immunized with DNA vector encoding an HIV epitope fused with hepatitis B surface antigen.", XP002183372, Database accession no. PREV199800126231 *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 2000, SELBY MARK ET AL: "Enhancement of DNA vaccine potency by electroporation in vivo.", XP002183376, Database accession no. PREV200000467774 *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; April 1999 (1999-04-01), MATHIESEN I: "Electropermeabilization of skeletal muscle enhances gene transfer in vivo.", XP002183374, Database accession no. PREV199900227202 *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; October 1999 (1999-10-01), SIN JEONG-IM ET AL: "DNA priming-protein boosting enhances both antigen-specific antibody and Th1-type cellular immune responses in a murine herpes simplex virus-2 gD vaccine model.", XP002183371, Database accession no. PREV200000068151 *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; October 1999 (1999-10-01), ZEWERT THOMAS E ET AL: "Creation of transdermal pathways for macromolecule transport by skin electroporation and a low toxicity, pathway enlarging molecule.", XP002183373, Database accession no. PREV200000412516 *
DATABASE MEDLINE [online] US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; SMITH L C ET AL: "Advances in plasmid gene delivery and expression in skeletal muscle.", XP002183375, retrieved from STN Database accession no. 2001206600 *
DNA AND CELL BIOLOGY, vol. 18, no. 10, October 1999 (1999-10-01), pages 771 - 779, ISSN: 1044-5498 *
GENE THERAPY, vol. 6, no. 4, April 1999 (1999-04-01), pages 508 - 514, ISSN: 0969-7128 *
JOURNAL OF BIOTECHNOLOGY, vol. 83, no. 1-2, 2000, pages 147 - 152, ISSN: 0168-1656 *
KADOWAKI SHIN-ETSU ET AL: "Protection against influenza virus infection in mice immunized by administration of hemagglutinin-expressing DNAs with electroporation.", VACCINE, vol. 18, no. 25, 2000, pages 2779 - 2788, XP002183369, ISSN: 0264-410X *
MENDIRATTA SANJEEV KUMAR ET AL: "Therapeutic tumor immunity induced by polyimmunization with melanoma antigens gp100 and TRP-2.", CANCER RESEARCH, vol. 61, no. 3, 1 February 2001 (2001-02-01), pages 859 - 863, XP002183368, ISSN: 0008-5472 *
VIROLOGY, vol. 240, no. 2, 20 January 1998 (1998-01-20), pages 304 - 315, ISSN: 0042-6822 *
ZUCCHELLI S ET AL: "Enhancing B- and T-cell immune response to a hepatitis C virus E2 DNA vaccine by intramuscular electrical gene transfer.", JOURNAL OF VIROLOGY, (2000 DEC) 74 (24) 11598-607., XP002183370 *

Also Published As

Publication number Publication date
US20030065362A1 (en) 2003-04-03
US20060041219A1 (en) 2006-02-23
US6261281B1 (en) 2001-07-17
US6958060B2 (en) 2005-10-25
US20080147131A1 (en) 2008-06-19
US7931640B2 (en) 2011-04-26
WO2001085202A2 (fr) 2001-11-15
US20040092907A1 (en) 2004-05-13
US20020038112A1 (en) 2002-03-28
US6610044B2 (en) 2003-08-26
AU5493201A (en) 2001-11-20
EP1280550A2 (fr) 2003-02-05

Similar Documents

Publication Publication Date Title
WO2001085202A3 (fr) Procede d'introduction de molecules dans des cellules
PL337583A1 (en) Improved method of transferring nucleic acid to a striated muscle and connection enabling accomplishment of this method
AU2001234857A1 (en) Electroporation and electrophoresis system and method for achieving molecular penetration into cells in vivo
DE3369466D1 (en) Fused genes encoding hybrid proteins, cloning vectors containing them and the use thereof
DE69816801D1 (de) Bodenstromversorgung fur ein elektrisches fahrzeug mit erdverbindungsvorrichtung
AU5776594A (en) Defibrillation method and apparatus
WO2005049108A3 (fr) Systeme et methode d'administration transdermique
WO2002068040A3 (fr) Appareil pour stimuler le muscle d'un sujet
AU2001245852A1 (en) Stimulatory device and methods to electrically stimulate the phrenic nerve
AU4778101A (en) Novel polypeptides, and nucleic acids encoding the same
DE69414686D1 (de) Elektrische verbindungsstruktur und verfahren zum elektrischen verbinden von anschluessen untereinander
DE3675887D1 (de) Elektronisch leitfaehige stickstoffpolymere, verfahren zur herstellung derselben, elektrochronische anzeigezelle, und diese polymere verwendender elektrochemischer generator.
ZA200204384B (en) A body formed of set, initially pasty material and including an electrically conducting path and a method of making such a body.
PT84525A (fr) Connecteur de derivation monobloc notamment pour lignes electriques sous tension
MX9602820A (es) Metodo y aparato para detectar cambios en el estado de un lecho de resina.
DE69734586D1 (de) Retinoid-metabolisierendes protein
WO1987007472A3 (fr) Sequence d'adn codant le mas oncogene, polypeptides codes a partir de ce dernier, et diagnostic et autres methodes fondees sur celui-ci
ATE110498T1 (de) Einrichtung zum elektrischen verbinden von einschiebbaren elektrischen baugruppen.
IL131103A0 (en) The neurotrophic factor nnt-1
ATA138388A (de) Betonfundament fuer stahlmasten von elektrischen hochspannungsleitungen, skiliften u.dgl.
PT93934A (pt) Dispositivo e metodo para a libertacao iontoforetica de farmacos
BOKOR Joint Services Electronics Program(Final Report, 6 Jun. 1994- 5 Feb. 1997)
WO2001040258A3 (fr) Trousse pedagogique et methode utilisant un gene et une proteine stimule par le facteur de necrose tumorale
RU96114776A (ru) Способ лечения мегаколон у детей
GB9800637D0 (en) An electrically insulating connector,assemblies and methods

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ CZ DE DE DK DK DM DZ EE EE ES FI FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ CZ DE DE DK DK DM DZ EE EE ES FI FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2001928065

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2001928065

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2001928065

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP